title: Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells.
abstract: Resveratrol, a dietary phytoalexin, has emerged as a promising chemopreventive agent due to its antiproliferative and pro-apoptotic action toward cancer cells and its ability to inhibit tumor growth in animals. Gastric adenocarcinoma cells respond to resveratrol treatment with suppression of DNA synthesis, activation of nitric oxide synthase, induction of apoptosis and inhibition of total PKC and PKC alpha activity. Here we demonstrate that treatment of gastric adenocarcinoma SNU-1 cells with resveratrol results in time and concentration dependent accumulation of tumor suppressors p21(cip1/WAF-1) and p53 and is preceded by loss of membrane-associated PKC delta protein and a concomitant increase in cytosolic PKC alpha. Arrest of the cell cycle at transition of S to G(2)/M phases correlates with the profile of (3)H-thymidine incorporation and accumulation of p21(cip1/WAF-1) and was temporally dependent on increase of p53. SNU-1 cells respond to resveratrol treatment with up-regulation of both Fas and Fas-L proteins, whereas in KATO-III cells, with deleted p53, only Fas-L is increased after resveratrol treatment. Although Fas and Fas-L proteins in SNU-1 cells and Fas-L in KATO-III cells were elevated within 24 h of cell treatment with low concentrations of resveratrol, significant apoptotic response at these concentrations was observed only after 48 h. Altogether, our findings indicate that resveratrol engages PKC alpha and delta signals in gastric adenocarcinoma SNU-1 cells prior to up-regulation of antiproliferative and pro-apoptotic signals. The specific cell death signals engaged by resveratrol appear to be cell type dependent and suggest that resveratrol has chemopreventive potential even after mutational changes have occurred.
authors.affiliation: Department of Medicine Division of Gastroenterology, Cook County Hospital, Chicago, IL 60612, USA.
authors.forename: Mary Jo
authors.initials: MJ
authors.lastname: Atten
authors.forename: Ernesto
authors.initials: E
authors.lastname: Godoy-Romero
authors.forename: Bashar M
authors.initials: BM
authors.lastname: Attar
authors.forename: Thomas
authors.initials: T
authors.lastname: Milson
authors.forename: Matthew
authors.initials: M
authors.lastname: Zopel
authors.forename: Oksana
authors.initials: O
authors.lastname: Holian
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D053222:Fas Ligand Protein; D006801:Humans; D008562:Membrane Glycoproteins / Q000187:drug effects*; D019001:Nitric Oxide Synthase / Q000096:biosynthesis*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D000077185:Resveratrol; D013267:Stilbenes / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control
chemical_list: D016588:Anticarcinogenic Agents; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D013267:Stilbenes; D019001:Nitric Oxide Synthase; D011493:Protein Kinase C; D000077185:Resveratrol
references.citation: Biochim Biophys Acta. 2003 Jan 20;1637(1):59-69
references.pmid: 12527408
references.citation: Drugs Exp Clin Res. 1999;25(2-3):79-85
references.pmid: 10370868
references.citation: Semin Cancer Biol. 1998;8(5):345-57
references.pmid: 10101800
references.citation: Clin Cancer Res. 2001 May;7(5):1466-73
references.pmid: 11350919
references.citation: Rev Physiol Biochem Pharmacol. 2001;142:1-96
references.pmid: 11190577
references.citation: Biochemistry. 1999 Oct 5;38(40):13244-51
references.pmid: 10529197
references.citation: Oncogene. 2000 May 4;19(19):2331-7
references.pmid: 10822384
references.citation: Int J Oncol. 1998 Apr;12(4):865-9
references.pmid: 9499448
references.citation: Microbios. 2001;104(408):79-85
references.pmid: 11297014
references.citation: J Exp Med. 1996 Dec 1;184(6):2399-404
references.pmid: 8976194
references.citation: Int J Cancer. 2001 Dec 1;94(5):615-22
references.pmid: 11745454
references.citation: J Biol Chem. 1997 Jan 24;272(4):2452-8
references.pmid: 8999958
references.citation: J Biol Chem. 2000 Mar 17;275(11):7574-82
references.pmid: 10713064
references.citation: Cancer Lett. 2000 Feb 1;148(2):181-8
references.pmid: 10695995
references.citation: Int J Hematol. 2000 Jul;72(1):12-9
references.pmid: 10979203
references.citation: J Exp Med. 1998 Dec 7;188(11):2033-45
references.pmid: 9841917
references.citation: Gen Pharmacol. 1998 Nov;31(5):721-8
references.pmid: 9809468
references.citation: J Pharm Pharmacol. 2000 Oct;52(10):1287-95
references.pmid: 11092574
references.citation: Carcinogenesis. 2000 Aug;21(8):1619-22
references.pmid: 10910967
references.citation: FASEB J. 2001 Aug;15(10):1798-800
references.pmid: 11481234
references.citation: Cancer Res. 2002 May 1;62(9):2488-92
references.pmid: 11980638
references.citation: Br J Haematol. 2000 May;109(2):405-12
references.pmid: 10848832
references.citation: Cancer Res. 2000 Jul 1;60(13):3477-83
references.pmid: 10910059
references.citation: Leuk Res. 1998 Jul;22(7):597-604
references.pmid: 9680109
references.citation: Hepatology. 1998 May;27(5):1265-74
references.pmid: 9581680
references.citation: J Biol Chem. 2003 Oct 17;278(42):41482-90
references.pmid: 12902349
references.citation: Am J Physiol Gastrointest Liver Physiol. 2002 May;282(5):G809-16
references.pmid: 11960777
references.citation: Science. 1997 Jan 10;275(5297):218-20
references.pmid: 8985016
references.citation: Biochem Biophys Res Commun. 1998 Sep 8;250(1):53-8
references.pmid: 9735330
references.citation: J Nutr. 2001 Aug;131(8):2197-203
references.pmid: 11481417
references.citation: Biochem J. 1999 Dec 15;344 Pt 3:921-8
references.pmid: 10585882
references.citation: Am J Gastroenterol. 2000 Jul;95(7):1849
references.pmid: 10926010
references.citation: J Med Chem. 1993 Oct 1;36(20):2950-5
references.pmid: 8411012
references.citation: J Cell Physiol. 1999 Jun;179(3):297-304
references.pmid: 10228948
references.citation: Biochem Pharmacol. 2001 Nov 15;62(10):1423-32
references.pmid: 11709203
references.citation: Circ Res. 1994 Feb;74(2):299-309
references.pmid: 8293569
references.citation: Cancer Lett. 2001 Feb 10;163(1):43-9
references.pmid: 11163107
references.citation: Mol Pharmacol. 2002 Oct;62(4):772-7
references.pmid: 12237323
references.citation: J Biol Chem. 1951 Nov;193(1):265-75
references.pmid: 14907713
references.citation: Cancer Surv. 1996;27:213-48
references.pmid: 8909803
references.citation: Clin Cancer Res. 2002 Mar;8(3):893-903
references.pmid: 11895924
references.citation: Pathol Res Pract. 1998;194(5):309-17
references.pmid: 9651943
references.citation: Hunan Yi Ke Da Xue Xue Bao. 1998;23(5):441-3
references.pmid: 10682555
references.citation: FEBS Lett. 1996 Jun 17;388(2-3):195-9
references.pmid: 8690086
references.citation: Cancer Metastasis Rev. 1994 Dec;13(3-4):411-31
references.pmid: 7712599
references.citation: Bone Marrow Transplant. 2000 Mar;25(6):639-45
references.pmid: 10734298
references.citation: Cell Death Differ. 2000 Sep;7(9):834-42
references.pmid: 11042678
references.citation: Biochem Pharmacol. 2000 Nov 1;60(9):1355-9
references.pmid: 11008129